PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-249.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-146.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-145.19%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-145.19%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.81%
OCF growth above 1.5x AVXL's 17.78%. David Dodd would confirm a clear edge in underlying cash generation.
39.81%
FCF growth above 1.5x AVXL's 17.78%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.38%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
21.38%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
21.38%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-13.41%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-13.41%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-13.41%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-423.21%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-423.21%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-423.21%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-10.94%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
4.78%
We have some new debt while AVXL reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
231.81%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.